The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

LONDON — Sanofi on Tuesday said it would buy the vaccine-focused biotech Vicebio for more than $1 billion upfront, picking up an experimental shot targeting RSV and a vaccine approach that is ...

Vicebio is currently running an exploratory Phase 1 clinical trial with lead asset VXB-241, a bivalent vaccine targeting both RSV and hMPV viruses, pathogens that are a significant burden in the ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of ...

Vicebio is the latest biotech to eye up the RSV market, a space that has seen a buzz of development over the last year. Pharma giants GSK, Pfizer and Moderna have all brought vaccines for the ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

LONDON, July 22, 2025 /PRNewswire/ -- Vicebio Ltd ("Vicebio" or the "Company"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...